29.03.2017
Medios AG DE000A1MMCC8
DGAP-News: Medios AG invests in significant expansion of production capacities for personalised medicines
DGAP-News: Medios AG / Key word(s): Expansion/Real Estate
Medios AG invests in significant expansion of production capacities for
personalised medicines
29.03.2017 / 16:19
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News
Medios AG invests in significant expansion of production capacities for
personalised medicines
- Speciality Pharma company buys property including building in
Berlin-Charlottenburg
- Construction of new manufacturing facility planned, with latest technology
and higher productivity
- Production capacity can be increased fivefold by 2020
Berlin, 29 March 2017 - Medios AG, a competence partner and solution
provider in the Speciality Pharma segment, has today acquired a property for
significantly expanding the production capacities of its subsidiary Medios
Manufaktur GmbH and merging the activities of the Medios Group on one site.
The property is situated in an industrial estate in Berlin-Charlottenburg.
It comprises 3,195 square metres of land and an office building. Including
the expansion of production capacities and the construction of another
building, total investment on this property will come to around EUR 11
million.
Manfred Schneider, Chief Executive Officer of Medios AG: "The property is
perfectly suited for implementing our growth strategy. It has enough space
to merge all the companies of the Medios Group on one site in the medium
term. That will enable us to optimise our business processes, make better
use of synergies and reduce costs. The location is also future-proof,
because we can successively expand the production capacities of Medios
Manufaktur there significantly, depending on requirements. Capacities for
manufacturing individual patient infusions can be increased fivefold by
2020, for example."
Planning has already begun on expanding production capacities and the
construction work is due to be completed by late 2018. The office building
on the purchased property has a total area of approx. 2,000 square metres
and is to be used for the business operations of Medios Manufaktur GmbH.
Another building with up to 3,000 square metres of floor space is also to be
built to accommodate Medios AG, Medios Pharma GmbH and Medios Digital GmbH.
The funds for the acquisition of the property and the necessary alterations
come partly from the net proceeds of the cash capital increase carried out
by Medios AG in December 2016. As announced in the securities prospectus in
November 2016, the intention was to invest up to EUR 11 million to purchase
a property, erect a building and equip the laboratories and offices.
For the ongoing operations, Medios AG and its subsidiaries Medios Pharma
GmbH, Medios Manufaktur GmbH and Medios Digital GmbH are currently renting
five offices at different locations in Berlin. The central location of the
future group headquarters will continue to ensure that all customers and
partners in Berlin are supplied on time and at short notice.
About Medios AG
Medios AG positions itself - along with its sister companies Medios Pharma,
Medios Manufaktur and Medios Digital - as a competence partner and solution
provider for the Specialty Pharma segment. Medios AG interconnects
individual actors within the market and turns them into co-operating
partners. It is our goal to guarantee best possible pharmaceutical care for
patients while providing our partners and clients with integrated solutions
along the supply chain. Specialty Pharma medicine are pharmaceuticals for
patients with rare and chronic diseases such as certain cancer types and
autoimmune / infectious diseases, which are time-consuming and
cost-intensive to cure.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Telefon: +49 40 60918618
Fax: +49 40 60918660
E-mail: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the
forward-looking statements contained in this notification.
---------------------------------------------------------------------------
29.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
559161 29.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1